Jacqualyn A. Fouse net worth and biography

Jacqualyn Fouse Biography and Net Worth

CEO & Director of Agios Pharmaceuticals

Dr. Fouse has served as a member of our board of directors since December 2017. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017. Dr. Fouse joined Celgene in 2010 as chief financial officer and was named president of the company’s global hematology & oncology franchise in 2014. Before joining Celgene, Dr. Fouse served as chief financial officer of Bunge Limited, a leading global agribusiness and food company. Prior to Bunge, she served as senior vice president, chief financial officer, and head of corporate strategy at Alcon Laboratories, a leading ophthalmic pharmaceutical and medical device company. Prior to her tenure with Alcon, she held a variety of senior leadership roles with international companies, spending almost a decade of her career in Switzerland. Dr. Fouse earned her B.A. and M.A. in economics and a Ph.D. in finance from the University of Texas at Arlington.

How do I contact Jacqualyn A. Fouse?: The corporate mailing address for Dr. Fouse and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on Jacqualyn A. Fouse's contact information.
Has Jacqualyn A. Fouse been buying or selling shares of Agios Pharmaceuticals?: Jacqualyn A. Fouse has not been actively trading shares of Agios Pharmaceuticals in the last ninety days. Learn More on Jacqualyn A. Fouse's trading history.
Who are Agios Pharmaceuticals' active insiders?: Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Agios Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 76,141 shares worth more than $2,110,887.90. The most recent insider tranaction occured on September, 26th when CFO Cecilia Jones sold 2,542 shares worth more than $124,634.26. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.
Information on this page was last updated on 9/26/2024.

Jacqualyn A. Fouse Insider Trading History at Agios Pharmaceuticals

Jacqualyn A. Fouse Buying and Selling Activity at Agios Pharmaceuticals

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $53.78

$52.74

$55.67

50 Day Range

MA: $46.44

$40.50

$60.46

2 Week Range

Now: $53.78

$20.96

$62.58

Volume

926,067 shs

Average Volume

704,416 shs

Market Capitalization

$3.07 billion

P/E Ratio

4.73

Dividend Yield

N/A

Beta

0.75

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.